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Abstract
The histiocytoses are a heterogeneous group of disorders characterised by an excessive number of histiocytes. In most cases
the pathophysiology is unclear and treatment is nonspecific. Faisalabad histiocytosis (FHC) (MIM 602782) has been classed
as an autosomal recessively inherited form of histiocytosis with similarities to Rosai-Dorfman disease (RDD) (also known as
sinus histiocytosis with massive lymphadenopathy (SHML)). To elucidate the molecular basis of FHC, we performed
autozygosity mapping studies in a large consanguineous family and identified a novel locus at chromosome 10q22.1.
Mutation analysis of candidate genes within the target interval identified biallelic germline mutations in SLC29A3 in the FHC
kindred and in two families reported to have familial RDD. Analysis of SLC29A3 expression during mouse embryogenesis
revealed widespread expression by e14.5 with prominent expression in the central nervous system, eye, inner ear, and
epithelial tissues including the gastrointestinal tract. SLC29A3 encodes an intracellular equilibrative nucleoside transporter
(hENT3) with affinity for adenosine. Recently germline mutations in SLC29A3 were also described in two rare autosomal
recessive disorders with overlapping phenotypes: (a) H syndrome (MIM 612391) that is characterised by cutaneous
hyperpigmentation and hypertrichosis, hepatomegaly, heart anomalies, hearing loss, and hypogonadism; and (b) PHID
(pigmented hypertrichosis with insulin-dependent diabetes mellitus) syndrome. Our findings suggest that a variety of
clinical diagnoses (H and PHID syndromes, FHC, and familial RDD) can be included in a new diagnostic category of SLC29A3
spectrum disorder.
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Introduction
Histiocytosis encompasses a group of diverse disorders char-
acterised by the accumulation and infiltration of monocytes,
macrophages, and dendritic cells in the affected tissues. The
nomenclature and classification of paediatric histiocytic disorders
is complex but the most recent classification describes three major
classes of histiocytoses in which the most common are class I and
II [1–3]. Class I comprises dendritic cell disorders such as
Langerhans cell histiocytosis (LCH) (also known as histiocytosis X),
PLoS Genetics | www.plosgenetics.org 1 February 2010 | Volume 6 | Issue 2 | e1000833and includes the syndromes Letterer-Siwe disease (MIM 246400)
and Hand-Schu ¨ller-Christian disease. Class II consists of macro-
phage-related disorders including hemophagocytic lymphohistio-
cytosis (HLH) which is characterised by inherited (Familial
haemophagocytic lymphohistiocytosis) (FHLH) (MIM 267700)
and sporadic forms of the disease. Class III comprises malignant
disorders involving histiocytic lineage cells including histiocytic
lymphoma and acute monocytic leukaemia. Additional, less
common, histiocytic disorders included in class II are Sinus
histiocytosis with massive lymphadenopathy (SHML, Rosai-Dorf-
man syndrome), Xanthogranuloma, Reticulohistiocytoma and a
familial form previously designated as Faisalabad histiocytosis [4].
Familial forms of histiocytosis are rare [1]. FHLH can be caused
by mutations in the perforin genes (PRF1 and PRF2), MUNC 13-4
and syntaxin 11 [5]. Faisalabad histiocytosis (MIM 602782) was
first described as a novel autosomal recessive form of histiocytosis
in a highly consanguineous family originating from Pakistan [4].
Affected individuals were born with joint deformities, sensorineu-
ral hearing loss and subsequently developed a generalized
lymphadenopathy and swellings in their eyelids that were shown
to contain histiocytes. The phenotype of Faisalabad histiocytosis
overlaps with that of Rosai-Dorfman disease (RDD or sinus
histiocytosis with massive lymphadenopathy (SHML)), a histiocytic
disorder characterized by painless but protracted lymphadenop-
athy with lymph node histology showing large histiocytes with
voluminous clear cytoplasm, rounded nuclei and emperipolesis.
RDD is mostly sporadic but inherited cases can occur and
Rossbach et al [6] highlighted the phenotypic similarity between
familial RDD and FHC. In order to elucidate the molecular basis
of FHC and familial RDD we undertook gene mapping and
identification studies in three affected families.
Results
Mapping of a novel locus for Faisalabad Histiocytosis to
chromosome 10q22.1
Three families were ascertained for gene mapping studies. Family
1 is the large consanguineous family with Faisalabad histiocytosis
that was reported previously [4]. Family 2 is a Turkish family with
three affected brothers with sinus histiocytosis with massive
lymphadenopathy [7]. Family 3 is a Palestinian consanguineous
family with 2 affected brothers and described previously [6].
A genome-wide linkage scan was performed using Affymetrix
250k SNP arrays in 8 affected individuals from the three families.
The largest region of homozygosity shared by affected individuals
in Family 1 was at chromosome 10q22.1 from 71,226,316 to
72,850,116 bp (rs12411657 and rs10999804). The two affected
children from Family 3 also demonstrated a homozygous region at
chromosome 10q22.1 between rs10509322 and rs16931177
(71,781,854–75,540,896 bp) that partially overlapped the minimal
region in Family 1. Genotyping of all available family members of
Families 1 and 3 with microsatellite markers D10S537
(,72,065,347 bp) and D10S1432 (,74,329,402 bp) confirmed
linkage and provided a maximum multipoint LOD score at
D10S1432 (Zmax=4.79). Although the affected children in Family
2 (Turkish) were not homozygous at chromosome 10q22.1, the
SNP haplotypes were identical in all 3 affected children and were
therefore consistent with linkage (data not shown). A common
region of autozygosity was apparent in all affected members of
families 1 and 3 which gave a minimal candidate region of
1.068262 Mb between SNPs rs10509322 (71,781,854 bp) and
rs10999804 (72,850,116 bp) on chromosome 10q22.1.
Mutation analysis of candidate genes and identification
of SLC29A3 mutations
The 1 Mb candidate region on chromosome 10q22.1 contained
11 genes (Figure 1) including Perforin (PRF1) which is mutated in
patients with HLH (5). Direct sequencing of the coding region and
flanking intronic sequences revealed no mutations in PRF1 or in the
putative tumour suppressor UNC5B [8]. However, direct sequencing
of SLC29A3 identified mutations in all three families (Figure 1). Thus
a homozygous splice site mutation at the first base of the second
intron (c.300+1G.A) was found in family 1. Lymphocyte RNA was
obtained from a heterozygous carrier (VII: 9) of the c.300+1G.A
mutation and RT-PCR was performed. This revealed monoallelic
expression (A allele detected) of an exon 2 coding region SNP
(rs2277257) although the individual was heterozygous (A/G) in
genomic DNA. No abnormally sized transcripts were detected
consistent with lack of expression from the mutant allele secondary
to nonsense mediated RNA decay (Figure 2). A homozygous
missense substitution was detected in all affected individuals in
Family 3 (c.1309 G.A; p.Gly437Arg). The p.Gly437 residue occurs
within the tenth transmembrane region of the protein and is highly
conserved across species (data not shown). Affected individuals in
Family 2 were compound heterozygotes for the p.Gly437Arg and a
frameshift mutation (c.307delTT) that was predicted to produce an
immediate stop codon (p.Phe103X). All mutations found in the
three families segregated with the disease and were not detected in
ethnically matched control chromosomes (Asian controls n=384,
Turkish controls n=192 and Arab controls n=84).
Analysis of the growth-suppressing activity of SLC29A3
Although the lymphadenopathy in Rosai-Dorfman disease is
considered a reactive rather than a neoplastic process, the occurrence
of two early onset cancers in the proband of Family 1 (see Table 1)
raised the possibility that SLC29A3 inactivation might cause cancer
susceptibility. Hence we investigated whether SLC29A3 might
suppress cell growth using in vitro colony formation assays. Following
transfection of a wild-type SLC29A3 expression plasmid into
HEK293 cells there was a significantly reduced number of G418-
resistant colonies (mean reduction 58%, P=0.005) compared with
HEK293 cells transfected with an empty vector control (Figure 3). In
contrast, transfection of mutant constructs (p.Gly437Arg and
c.307delTT) did not significantly affect colony formation (mean
change compared to empty vector 3.5% and 0% respectively).
SLC29A3 siRNA inhibits SLC29A3 gene expression and
promotes cell proliferation
To further investigate the effect of SLC29A3 on cell growth
HeLa cells were treated with siRNA against SLC29A3 (120032-
siRNA and 26642-siRNA) or with a luciferase control sequence
(control-siRNA). Compared with transfection by the luciferase
Author Summary
The histiocytoses are a group of systemic disorders
usually confined to childhood and are caused by an
excessive number of histiocytes which phagocytose other
cells and process antigens. Although nearly a century has
passed since histiocytic disorders were recognised, their
pathophysiology remains largely unclear, and treatment
is nonspecific. The identification of SLC29A3 mutations as
the molecular basis for a familial form of syndromic
histiocytosis (FHC/RDD) confirms a direct link between
Faisalabad histiocytosis and Rosai-Dorfman disease
and links these disorders to other SLC29A3-associated
phenotypes.
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than 80% in HeLa cells using 120032-siRNA and by 95% using
the 26642-siRNA (Figure 4A). Knockdown of SLC29A3 by siRNA
increased cell proliferation after 72 hours when compared with
control cells (control-siRNA transfection) (Figure 4B).
SLC29A3 expression in mouse embryos
Faisalabad histiocytosis displays a combination of generalized and
tissue specific clinical features (short stature and deafness). To reveal
potential target tissues for SLC29A3 during embryonic development,
we determined the slc29a3 expression pattern in mouse embryos by
in situ hybridization. Within e10.5 and e12.5 embryos, weak
ubiquitous slc29a3 expression is seen throughout the embryo (data
not shown). At e12.5, increased expression levels within some tissues
begin to be noticeable and are more readily apparent by e14.5 (see
Figure 5). Marked expression is seen throughout the central nervous
system including the spinal cord and brain particularly in more
dorsal most regions. A number of peripheral nervous system ganglia
Figure 2. Loss of expression of mutant allele due to IVS2+1G .A splice-site mutation identified in family 1. PCR and sequencing
analysis from the genomic DNA of a mutation carrier from family 1 shows heterozygous state of SNP rs2277257 (G/A). Subsequent RT–PCR and
sequencing analysis of SLC29A3 transcript shows lack of the ‘G’ allele and therefore loss of mRNA expression.
doi:10.1371/journal.pgen.1000833.g002
Figure 1. Schematic showing the minimal candidate interval on chromosome 10q22.1, positions of candidate genes taken from the
Ensembl genome browser (Build 49), genomic organization of SLC29A3, and positions of mutations found in the 3 histiocytosis
syndrome families.
doi:10.1371/journal.pgen.1000833.g001
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PLoS Genetics | www.plosgenetics.org 3 February 2010 | Volume 6 | Issue 2 | e1000833Table 1. Comparison of clinical features of families with SLC29A3 mutations from this report and those reported with H syndrome
and PHID syndrome.
Clinical
diagnosis Faisalabad histiocytosis Familial SHML
Familial Rosai Dorfman
disease/Faisalabad
histiocytosis H syndrome
Pigmented hypertrichosis
with insulin dependent
diabetes mellitus syndrome
OMIM reference 602782 612391
Literature
reference
Moynihan et al (1998) Kismet et al (2005) Rossbach et al (2005) Mohlo-Pessach et al (2008) Cliffe et al (2009)
Inheritance Autosomal recessive Autosomal recessive Autosomal recessive Autosomal recessive Autosomal recessive
Number of
kindreds and
ethnic origin
1 (Pakistani) 1 (Turkish) 1 (Palestinian) 10 (9 Arab and one
Bulgarian)
5( 1N o r t hA m e r i c a nC a u c a s i a n ,1
Indian, 1 Pakistani and 2 Lebanese)
Skin Hyper-pigmentation
lower extremities
Hyperpigmented and
hypertrichotic patches
Pigmented hypertrichotic skin
lesions
Heart Small ASD (one case) PS, PDA
Ear Sensorineural deafness Sensorineural deafness Sensorineural deafness Sensorineural hearing loss No deafness
Abdomen Hepatomegaly Hepatosplenomegaly Hepatosplenomegaly
Growth Short stature Short stature Short stature Short stature Short stature
Endocrine Hypogonadism Gynaeocomastia
Hypogonadism
Delayed puberty
Pancreas Occasional hyperglycaemia IDDM in .80% of cases
Severe pancreatic exocrine
deficiency (two cases)
Eyes Eyelid swellings due to
histiocytic deposits
Rapidly growing orbital
mass with SHML
histopathology
Uveitis (1/2 cases) Exophthalmos with normal
thyroid function
Hands Progressive contractures
of the fingers
Camptodactyly, flexion
contractures of hands
No abnormality
Feet Progressive contractures
of toes
Hallux valgus with
fixed flexion contractures
of toe joints
Haematological
features
Bone marrow : diverse
cytoplasmic inclusions in
phagocytes and reticulum
cells.
The bone marrow: non-
clonal myeloproliferative
Process. Numerous
monocytes and
histiocytes and moderate
myelofibrosis.
Red cell aplasia
due to myelofibrosis
in one patient
Lymph nodes Generalised
lymphadenopathy
Cervical, retropharyngeal
and submandibular
lymphadenopathy
Cervical, submandibular
and, bilateral inguinal
lymphadenopathy
Cervical, axillary and inguinal
lymphadenopathy
Histopathology Lymph node and eyelid show
reactive features with small
reactive lymphoid follicles
and histiocytes within
hyperglycaemiadilated
hyperglycaemiasinuses
hyperglycaemiaresembling
hyperglycaemiaRosai-
Dorfman disease
Lymph node: filling
of lymph node sinuses
with histiocytes, plasma
cells and lymphocytes.
Histiocytes had a benign
appearance, were CD-1a
negative but positive
for CD68 and S-100.
Lymph node: nodal
capsular fibrosis and
chronic inflammation,
prominent sinus
histiocytes.
Skin lesions show
polyclonal
perivascular
lymphohistiocytic
infiltration with numerous
plasma cells in the
dermis and subcutis
Other Nasal mucosa swellings
Contractures of the elbows
and ankle
Proband: invasive ductal
carcinoma grade 3 ER
negative breast aged 43
years and carcinoma bladder
(grade 3 papillary TCC)
age 46 years
Intra-uterine fractures
Ventriculomegaly
with communicating
hydrocephalus and
right lambdoid
suture stenosis
with subsequent
plagiocephaly
Pectus carinatum
SLC29A3
mutations
c.300+1G.A p.Gly437Argp.
Phe103X
p.Gly437Arg p.Gly427Ser
p.Gly437Arg
p.Leu349SerfsX56
p.Met116Arg; p.Tyr314ThrfsX91
p.Gly437Arg; p.Glu444X
p.Thr449Arg
Clinical details were taken from published reports and unpublished updated information for the three families included in the present study. Previously unreported
additional information is shown in bold. Mutation nomenclature used is based on reference sequence NM_018344.4. (Abbreviations: SHML=Sinus Histiocytosis with
Massive Lymphadenopathy; IDDM=Insulin dependent diabetes mellitus; ASD=atrial septal defect; PS=Pulmonary stenosis; PDA=patent ductus areteriosis;
TCC=transitional cell carcinoma).
doi:10.1371/journal.pgen.1000833.t001
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dorsal root ganglia. The eye shows moderate expression including
the neural retina and highly localised expression at the anterior
surface of the lens. In the developing ear, stronger expression can be
seen in the cochlea and semi-circular canals and associated ganglia.
Most striking is the expression of slc29a3 in a variety of endodermal
and epithelial-derived structures. Of particular note are the
significant slc29a3 expression levels in the luminal side of the
stomach and gut and in the developing lung bronchioles, glomeruli
of the cortical kidney and pancreatic primordial. The secretory
surface of the choroid plexus and the olfactory epithelium also show
distinct expression. Notable expression is seen in the outer layers of
the developing trunk skin epidermis and within hair follicles
(vibrissae) in the snout, (trunk follicles are not well developed at
this time). Other sites of increased slc29a3 expression included the
thymus and developing germ cells within the testes, with lower levels
in the liver.
Mutation analysis of SLC29A3 in breast and bladder
tumours and cancer cell lines
The combination of tumour suppressor activity of hENT3
and presence of breast and bladder cancer (at ages 43 and 46
years respectively) in the proband of family 1 (VII: 7) led us to
speculate that SLC29A3 mutations might predispose to epithelial
cancers and/or be mutated in sporadic breast and bladder
cancer. Initially we screened for SLC29A3 mutations in a panel
of 6 breast cancer cell lines (MCF7, HCC1143, HCC1395,
HCC1937, HCC1806 and HCC1419) and 37 bladder cancer
cell lines. No pathogenic mutations were detected but two
unclassified heterozygous variants were identified in two bladder
cancer cell lines (p.Gly163Val in 5637 and p.Leu281Pro in
VMCU B1). However both variants were also detected in
normal controls (p.Gly163Val was detected in 3 out of 180 and
p.Leu281Pro in 7 out of 174 control chromosomes tested).
Screening of 48 primary breast tumour DNAs found a
heterozygous germline amino acid substitution (p.Val407Met)
with no loss of heterozygosity in the tumour. The variant was
not detected in 400 control chromosomes and the p.Val407
residue was conserved in lower species (rat, mouse, chicken,
zebrafish, Xenopus and Drosophila).
Discussion
Although the Faisalabad histiocytosis gene was previously
mapped to chromosome 11q25 in Family 1 [4], reinvestigation
Figure 3. Colony formation assays of SLC29A3. HEK293 cells were
transfected with empty vector, SLC29A3, SLC29A3
F103X and SLC29A3
G437R.
Each experiment was done in triplicate. The mean number of colonies
counted in the empty vector plates was taken as 100%. Values are mean
6 SEM from 3 controls and 3 samples. * P=0.005 between wildtype
SLC29A3 vs. empty vector; ** P=0.0058 and *** P=0.0078 between
SLC29A3
F103X and SLC29A3
G437R mutants resp. vs. wildtype SLC29A3.
doi:10.1371/journal.pgen.1000833.g003
Figure 4. Knockdown of SLC29A3 expression by siRNA
enhanced proliferation of HeLa cells. (A) Effect of SLC29A3 siRNA
on levels of SLC29A3 mRNA assessed by real-time quantitative PCR
(qRT–PCR). HeLa cells were treated with control or SLC29A3- 120032 or
SLC29A3-26642 siRNA for 72 hours. Cells were harvested and total RNA
was extracted. SLC29A3 and b-actin or SLC29A3 and b-2-microglobulin
mRNA (was examined by qRT-PCR. Values are mean 6 SEM from 3
controls and 3 samples. * P,0.001 between HeLa cells treated with
SLC29A3-siRNA versus luciferase siRNA control sequence. (B) SLC29A3
knockdown elevates proliferation in HeLa cells. HeLa cells were
transfected with siRNA designed to target SLC29A3 (siRNA-SLC29A3)o r
control siRNA. Cell proliferation assays were performed 72 hours after
siRNA transfection. Results areexpressed in fluorescence at 550 nm
using 580 nm as a reference wavelength(fluorescence is directly
proportional to the number of living cells). This figure represents 3
experiments.* P,0.05.
doi:10.1371/journal.pgen.1000833.g004
SLC29A3 Mutations in Familial Histiocytosis
PLoS Genetics | www.plosgenetics.org 5 February 2010 | Volume 6 | Issue 2 | e1000833of the family using high-density SNP arrays excluded the original
locus and identified a novel locus at chromosome 10q22.1. We
then identified germline SLC29A3 mutations in patients diagnosed
with syndromic forms of histiocytosis (Faisalabad histiocytosis and
familial RDD/SHML (fRDD)). RDD is classified as a reactive
macrophage histiocytosis. Histopathological analysis of lymph
nodes in patients with SLC29A3-associated FHC/RDD demon-
strate prominent sinus histiocytes with large vesicular nuclei and
abundant pale staining cytoplasm and emperipolesis. Langerhans
cell-type histiocytes are absent, and eosinophils are rare [6].
Affected patients have a polyclonal gammopathy. Interestingly, a
recent study has described germline SLC29A3 mutations in H
syndrome [9]. This autosomal recessive disorder is characterized
by cutaneous hyperpigmentation, hypertrichosis, hepatospleno-
megaly, heart anomalies, hearing loss, hypogonadism, short
stature, hallux valgus, and fixed flexion contractures of the toe
joints and the proximal interphalangeal joints [10]. Additionally,
another study has recently described germline SLC29A3 mutations
in an autosomal recessive disorder, PHID (Pigmented Hypertri-
chosis with Insulin dependent Diabetes mellitus) syndrome, which
is characterized by the childhood onset of pigmented hypertricho-
tic skin lesions associated with a high risk of insulin-dependent
diabetes mellitus [11]. Comparison of the clinical features of
families with germline SLC29A3 mutations demonstrates overlap-
ping features (see Table 1). Thus hyperpigmented skin lesions
(histological examination demonstrates polyclonal perivascular
lymphohistiocytic infiltration with numerous plasma cells in the
dermis and subcutis) are common to PHID and H syndrome and
were also seen in Family 3. Hearing loss and short stature is found
in H syndrome and in FHC/RDD. However deafness is not a
Figure 5. Expression of SLC29A3 mRNA in the mouse embryo. Sagittal sections from e14.5 embryos were processed for in situ hybridisation
followed by imaging of representative organs (hybridization signal corresponds to blue and red/pink is a general counterstain). While there is a level
ubiquitous expression throughout the embryo, several areas within the central and peripheral nervous system showed increased expression levels
particularly in the dorsal spinal cord (meninges and skin to the top) (A), dorsal anterior forebrain (B), dorsal posterior midbrain (C), dorsal root ganglia
(D), trigeminal ganglion (E), dorsal root ganglia (E), eye and anterior lens surface (F), ear (G), choroid plexus (H), and olfactory epithelium (I). Within
trunk organs localised expression is seen in the developing lung bronchioles (J), glomeruli of the kidney cortex (L), early pancreatic primordial (M),
gonads (N), thymus (O), internal mucosa of the gut (P) and stomach (Q), and lower level is the liver (K). Increased SLC29A3 expression is also seen in
the outer epidermal layer of the developing posterior ventral trunk skin (R). At e14.5 trunk hair follicles are not well-developed compared, however,
snout vibrissae (S,T) show elevated expression levels (a glancing more longitudinal section of an individual vibrassa can be seen in T). Scale bar in T is
100 um and applies to all images.
doi:10.1371/journal.pgen.1000833.g005
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is restricted to PHID. Patients with H syndrome and PHID may
have lymphadenopathy but do not have the life-threatening lymph
node enlargement seen in FHC/fRDD [9,11]. FHC/familial
RDD, H and PHID syndromes share some common features and
the phenotype of each disorder may vary between families. At
present, the reason for the phenotypic variability associated with
SLC29A3 mutations is unclear. In particular the p.Gly437Arg
mutation has been detected in H syndrome, PHID and FHC
patients (see Table 1) suggesting that genetic and/or environmen-
tal modifiers may be implicated. We suggest that these related
diseases might be viewed as manifestations of a ‘‘SLC29A3
spectrum disorder’’ (akin to the use of the ‘‘PTEN hamartoma
tumour syndrome’’ to cover several clinical diagnoses caused by
PTEN mutations). Further studies to determine the inter- and
intrafamilial phenotypic variability of ‘‘SLC29A3 spectrum
disorder’’ should provide insights into the molecular basis for
variations in clinical phenotype and the extent to which different
types of SLC29A3 spectrum disorder should be considered as
clinically distinct but related disorders or as a single entity with
variable expression. We found widespread expression of slc29a3 by
e14.5. It is interesting that some of the organs with prominent
expression (e.g. ear, testis and skin) are affected in patients with
FHC and/or H syndrome. However, we note that the clinical
phenotype of SLC29A3 spectrum disorder is more restricted than
might be predicted from the expression pattern as some tissues
with high expression of slc29a3 are clinically unaffected.
Nucleoside transport in mammalian cells is performed by two
types of transporters. The SLC28 family is responsible for active,
sodium-dependent nucleoside transport mainly in specialised cells.
In contrast the SLC29 protein family (also known as equilibrative
nucleoside transporters) are passive transporters and have a wide
tissue distribution. While hENT4 functions as an organic cation
transporter with minimal interaction with nucleosides or nucleo-
side analogues [12], hENT1, hENT2 and hENT3 have been
implicated in nucleoside transport and hENT3 has been reported
to be a broad selectivity, low affinity nucleoside transporter that
can transport adenine [13]. hENT3 was also reported to be a pH-
dependent intracellular transporter with partial localization to late
endosomes/lysosomes (the hENT1, 2 and 4 localise to the plasma
membrane) and to contain a (DE)XXXL(LI) endosomal/lysosomal
targeting motif [13]. However, recently it was reported that
endogenous hENT3 mainly localises to the mitochondria and is
predominantly a mitochondrial transporter [14]. Although germ-
line mutations in genes encoding the mitochondrial enzymes
succinate dehydrogenase and fumarate hydratase are associated
with neoplasia, these disorders do not show phenotypic overlap
with FHC/fRDD [15]. hENT3 has a similar broad permeant
selectivity for nucleosides and nucleobases and the availability of a
cytoplasmic pool of nucleosides is a key requirement for several
cellular processes including the nucleoside salvage pathway and
the generation of ATP/GTP for energy metabolism and signal
transduction pathways [16]. In view of two early onset cancers in a
proband with FHC we wondered whether SLC29A3 might
predispose to neoplasia (e.g. by altering adenosine metabolism as
extracellular adenosine has been reported to induce apoptosis and
proliferation in gastric, leukaemia and hepatic cancer cell lines
[17–20]). We found that ectopic expression of SLC29A3 sup-
pressed cell growth in vitro but did not find conclusive evidence of
SLC29A3 inactivation in breast or bladder cancers. Further clinical
studies are required to determine whether the frequency of
neoplasia in SLC29A3 spectrum disorder is increased or whether
the findings in the FHC family are coincidental. Interestingly,
knockdown of the Drosophila orthologue of SLC29A3 (dENT1)
results in a variety of phenotypes ranging from lethality in pupal
and pharate adult stages (with complete knockdown) or adult flies
with abnormal sensory bristle development (mild knockdown). The
latter phenotype has been linked to abnormalities of insulin
signalling pathway, and, in contrast to the growth suppressive
effects of hENT3 in human cell line, dENT1 appeared to be a
positive promoter of cell size or number. The identification of
genes for rare familial syndromes can provide insights into the
molecular pathogenesis of more common disorders. Hence the
analysis of the SLC29A3 pathway in sporadic Rosai-Dorfman
disease, will be of interest. It is unclear if SLC29A3 might prove to
be relevant to the pathogenesis of other non-familial histiocytic
disorders but we note that the use of nucleoside analogues for the
therapy of Langerhans cell histiocytosis has been suggested
previously [21].
Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
South Birmingham Research Ethics Committee (equivalent to the
Institutional Review Board of Birmingham Women’s Hospital)
reference number CA/5175. All patients provided written
informed consent for the collection of samples and subsequent
analysis.
Patient ascertainment
Three families previously published were ascertained for gene
mapping studies [4,6,7].
Gene mapping
A genome-wide linkage scan was carried out using the
Affymetrix 250K SNP chip in individuals affected with Faisalabad
Histiocytosis (Family 1; VI:6, VII:3 and VII:7); (Family 2; all 3
affected individuals); (Family 3; 2 affected individuals). This scan
excluded linkage to chromosome 11q25 and identified a single
region of extended homozygosity at chromosome 10q22.1 shared
by all three affected individuals of family 1 and the two affected
individuals of family 3. In addition all affected individuals of family
2 shared a disease haplotype for this region at chromosome 10.
These homozygous regions were further analysed by typing
microsatellite markers (D10S537 and D10S1432) in all family
members from whom DNA was available.
Mutation analysis
We identified positional candidate genes using data from the
National Centre for Biotechnology Information (NCBI) and
University of California Santa Cruz human genome databases.
Sequencing was performed using standard methods on an ABI
3730 automated sequencer. For SLC29A3, we designed primer
pairs using exon-primer to amplify exons 1–6, exon 6 was
amplified in 2 fragments. PCR primer sequences are available on
request.
Genomic DNA from 6 breast cancer cell lines (MCF7,
HCC1143, HCC1395, HCC1937, HCC1806 and HCC1419),
48 primary breast tumours, 37 bladder cancer cell lines, were used
for SLC29A3 mutation screening.
RT–PCR
Total RNA was extracted from human lymphocytes using the
RNeasy Mini Kit (Qiagen). cDNA was synthesized using random
primers and AMV reverse transcriptase using the Promega reverse
transcription system A3500 according to manufacturers’ instruc-
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primers: SLC29A3_1_FOR (59- AGCCCAGTGGTCCTGGC-
39) and SLC29A3_REV (59-CTAGATGAGGTGCACCAG-
GAGGGT-39), followed by a nested primer set SLC29A3_INT_
FOR (59-ATGGCCGTTGTCTCAGAGG-39) and SLC29A3_
INT_REV (59-GTAGAGGAGGGCCAG-39).
Plasmid constructs
A wild type construct of the full coding region of human
SLC29A3 was PCR amplified from the IMAGE clone 40116514
with primers: 59- GCTAGTCGACTTATGGCCGTTGTCT-
CAGAGG-39 and 59- CGATGGTACCCTAGATGAGGTG-
CACCAGGAGGGT-39. Forward primers contained a SalI
restriction site and reverse primers contained a KpnI site to allow
subcloning of the PCR fragments into the pEGFP-C2 vector (BD
Biosciences Clontech). The mutations p.Gly437Arg and
c.307delTT were created using the QuikChange site-directed
mutagenesis kit (Stratagene) with primers: SLC29A3_G437R_
FOR (59-CTGGCCCTCCTCTACAGGCCTAAGATTGTGC-
39), SLC29A3_G437R_REV (59-GCACAATCTTAGGCCTG-
TAGAGGAGGGCCAG-39), SLC29A3_307delTT_FOR (59-
GACATCCTGAACTACTGAGAGCTACCTTGC-39) and SL-
C29A3_307delTT_REV (59-GCAAGGTAGCTCTCAGTAG-
TTCAGGATGTC-39). All plasmid constructs were verified by
sequencing.
Cell culture
HeLa and HEK293 cells were routinely maintained in DMEM
(Sigma) supplemented with 10% fetal bovine serum at 37uC, 5%
CO2.
Colony formation assay
10 mg of empty vector or plasmid construct was transfected into
5610
5 HEK293 cells using Lipofectamine 2000 (Invitrogen)
according to manufacturers instructions and 48 h later cells were
seeded in a serial dilution and maintained in DMEM and 10%
fetal bovine serum supplemented with 1 mg/ml G418 (Invitro-
gen). Surviving colonies were stained with 0.4% crystal violet
(Sigma) in 50% methanol, 14 to 21 days after initial seeding, and
counted. Each transfection was carried out in triplicate.
SLC29A3 siRNA
HeLa cells were plated in 6-well plates at a density of 2610
5
cells per well prior to transfection with siRNA oligonucleotides.
After 24 h cells were transfected with two different predesigned
siRNAs (SLC29A3-120032 targeted to exon 6 and SLC29A3-
26642 targeted to exon 2 of SLC29A3) (Ambion) at a final
concentration of 3mM using INTERFERin (Polyplus transfection)
and OPTIMEM (Invitrogen). The firefly Luciferase (GL2) (CUG
ACG CGG AAU ACU UCG A) was used as a siRNA control.
Transfected cells were collected after 3 days incubation and
analysed for mRNA expression.
Real-time quantitative RT-PCR (RQ–PCR)
To determine whether SLC29A3 mRNA expression was altered
in siRNA transfected HeLa cells a RQ-PCR assay was developed
using TaqMan technology and an ABI 7900 HT analyser (Applied
Biosystems, Warrington, UK). RNA samples were isolated and
reverse-transcribed (as described above) and amplified with the
relevant primers using SYBR-Green based technology (SensiMix,
Quantace). Control samples were serially diluted to encompass the
range of expression levels encountered in HeLa cells. Gene
expression was quantified in terms of gene normalized copy
number (NCN) which was derived from the relevant standard
curve. The cDNA was diluted 1 in 5 for all samples and controls. A
control sample was then further diluted to give 1 in 5, 1 in 10
and 1 in 20 dilutions to make a standard curve. PCR reactions
were set up with primers for SLC29A3 (SLC29A3_FOR_59-
ATGGCCGTTGTCTCAGAGG-39 and SLC29A3_REV 59-
GGCAACGGCAAGGTAGCTCTC-39), and b-Actin (b-Actin_
FOR 59-GCGGGAAATCGTGCGTGACATT-39 and b-Actin_
REV 59-GATGGAGTTGAAGGTAGTTTCGTG-39) and b-2-
microglobulin (b-2M_FOR 59-CCTTGAGGCTATCCAGCGT-
39 and b-2M_REV 59-CCTGCTCAGATACATCAAACATG-
39) which acted as housekeeping genes. A 25ml real-time PCR
reaction mixture was then set up using SensiMix (26), 2.5 ml
cDNA and 0.2 mM gene-specific primers for SLC29A3, b-Actin and
b-2-microglobulin. Following the PCR the specificity was examined
on a 4% agarose gel. The real-time PCR result was then analysed
using the SDS 2.3 software and checked for a bimodal dissociation
curve or abnormal amplification plot. Each reaction was set up in
triplicate including a non-template control.
Cell proliferation assay
Reverse transfection of siRNA duplexes was performed at 3 nM
per well in a 96-well plate. Briefly 5610
3 HeLa cells (in 125 ml
media) were plated in 96-well plates and transfected with
INTERFERin and siRNA oligonucleotides designed to target
SLC29A3 (120032-siRNA and 26642-siRNA) or control luciferase
sequence as described previously. Then cell viability was assessed
after 48 hours using CellTiter-Blue cell viability assay (Promega)
according to the manufacturer’s instructions.
Analysis of slc29a3 expression in mouse embryogenesis
In situ hybridization was carried out as described previously [22]
u s i n ga na u t o m a t e dV e n t a n aD i s c o very platform (Tuscon, Arizona)
with minor modifications. C57BL/6J-Tyr
C-Brd albino mouse embryos
were collected humanely under UK animal licensing laws by a
schedule 1 procedure. Embryos were formalin-fixed and paraffin-
embedded followed by sectioning at 8mm in the sagittal orientation.
For comprehensive anatomical coverage of all embryonic organs at
e14.5 (EMAP ontology terms see http://www.emouseatlas.org/Atlas/
intro.html), every 10
th section was processed for in situ hybridisation.
Following hybridization, labelled antisense RNA probe for the mouse
slc29a3 gene (from position 1912 to 2230, RefSeq NM_023596) was
detected on the instrument using sheep anti-digoxygenin alkaline
phosphatase Fab fragments (Roche) followed by incubation with
BCIP/NBT (Roche). Sections were counterstained with neutral red,
mounted in Eukitt (SigmaAldrich) and photographed at 406 on a
Zeiss Axiskop 2 compound microscope. These in situ hybridisation
experiments formed part of a high-throughput studt at the Wellcome
Trust Sanger Institute in which over 400 genes on ,68,000 sections
were studied (see www.embryoexpress.org) in which positive and
negative in situ hybridization controls were routinely performed.
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